| Pharmaceuticals Industry | Healthcare Sector | Joseph T. Morrissey Jr. CEO | XSTU Exchange | - ISIN |
| US Country | 10,000 Employees | - Last Dividend | - Last Split | 2 Jun 2021 IPO Date |
Organon & Co. is a healthcare company focused on innovating and providing a range of health solutions specifically tailored towards women's health needs both in the United States and globally. The company's diverse product offering encompasses a variety of prescription therapies and medical devices. Founded in 2020 and headquartered in Jersey City, New Jersey, Organon & Co. has quickly positioned itself as a key player in women's health, extending its reach through a broad spectrum of contraception and fertility treatments, biosimilars, and other healthcare solutions. Their mission extends to addressing critical areas such as cardiovascular health, respiratory conditions, dermatology, bone health, and non-opioid pain management, catering to a wide demographic. Through its commitment to health innovation, Organon & Co. markets its products to a vast network of stakeholders including drug wholesalers, retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions.